Want to see AURA full AI Analyst Report?
Top Page
Aura Biosciences Inc
(NASDAQ:AURA)
Select Model
Select Model
Rating:43Neutral
Price Target:
$7.50
▲(2.88% Upside)
Action:Reiterated
Date:06/23/26
The score is held down primarily by weak financial performance typical of a pre-revenue biotech (no revenue, widening losses, and heavy ongoing cash burn). Technicals are also weak-to-mixed with negative MACD and the stock below its 50-day average, only partially offset by near-oversold RSI/Stoch readings. Valuation contributes limited support because negative earnings (negative P/E) and no dividend make standard valuation signals less actionable.
Positive Factors
Late-stage Phase 3 program nearing enrollment
A near-complete, registration‑enabling Phase 3 trial creates a clear long-term inflection point: positive topline results could enable regulatory filing and commercialization paths, materially de‑risking the business versus earlier-stage assets and concentrating value in a definable milestone.
Negative Factors
Pre-revenue with widening net losses
Being pre‑commercial with growing net losses means the company must rely on external capital until product sales begin. Continued negative earnings over time amplify funding needs and create execution risk if clinical setbacks delay potential revenue generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Late-stage Phase 3 program nearing enrollment
A near-complete, registration‑enabling Phase 3 trial creates a clear long-term inflection point: positive topline results could enable regulatory filing and commercialization paths, materially de‑risking the business versus earlier-stage assets and concentrating value in a definable milestone.
Read all positive factors
Aura Biosciences Inc (AURA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$800.60M
Dividend YieldN/A
Average Volume (3M)546.64K
Price to Earnings (P/E)―
Beta (1Y)1.61
Revenue GrowthN/A
EPS Growth7.21%
CountryUS
Employees106
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.77
Shares Outstanding103,436,420
10 Day Avg. Volume656,891
30 Day Avg. Volume546,640
Financial Highlights & Ratios
PEG Ratio-5.42
Price to Book (P/B)2.40
Price to Sales (P/S)0.00
P/FCF Ratio-3.86
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-587.63
Enterprise Value/Ebitda-3.03
Forecast
1Y Price Target
$20.67Price Target Upside183.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.6
Revenue Forecast (FY)N/A
Aura Biosciences Inc Business Overview & Revenue Model
Company Description
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platfo...
How the Company Makes Money
null...
Aura Biosciences Inc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
56
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -574.00K | 0.00 | 0.00 | -1.29M | 0.00 | 0.00 |
| EBITDA | -111.17M | -104.95M | -85.58M | -74.98M | -57.59M | -34.41M |
| Net Income | -112.39M | -106.19M | -86.92M | -76.41M | -58.76M | -35.25M |
Balance Sheet | ||||||
| Total Assets | 137.68M | 169.43M | 182.50M | 255.07M | 223.94M | 160.03M |
| Cash, Cash Equivalents and Short-Term Investments | 114.73M | 144.24M | 151.09M | 226.15M | 188.81M | 149.06M |
| Total Debt | 16.99M | 17.38M | 18.77M | 19.56M | 20.86M | 975.00K |
| Total Liabilities | 30.43M | 32.52M | 30.53M | 29.23M | 28.35M | 7.71M |
| Stockholders Equity | 107.25M | 136.91M | 151.97M | 225.85M | 195.58M | 152.31M |
Cash Flow | ||||||
| Free Cash Flow | -91.64M | -85.19M | -81.06M | -64.56M | -55.70M | -34.53M |
| Operating Cash Flow | -91.28M | -84.74M | -79.81M | -63.85M | -54.60M | -32.41M |
| Investing Cash Flow | 60.68M | 35.59M | 68.82M | -113.96M | -67.87M | -2.13M |
| Financing Cash Flow | 77.36M | 77.16M | 1.59M | 97.29M | 95.63M | 166.26M |
Aura Biosciences Inc Technical Analysis
Positive
7.29
Price Trends
7.22
Positive
6.73
Positive
6.28
Positive
Market Momentum
0.02
Negative
63.13
Neutral
75.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AURA, the sentiment is Positive. The current price of 7.29 is above the 20-day moving average (MA) of 6.68, above the 50-day MA of 7.22, and above the 200-day MA of 6.28, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 63.13 is Neutral, neither overbought nor oversold. The STOCH value of 75.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AURA.
Aura Biosciences Inc Risk Analysis
Aura Biosciences Inc disclosed 69 risk factors in its most recent earnings report. Aura Biosciences Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aura Biosciences Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $679.59M | -4.89 | -36.83% | ― | 383560.87% | 20.87% | |
57 Neutral | $976.83M | -13.03 | -33.07% | ― | ― | -20.34% | |
53 Neutral | $201.92M | -1.20 | -117.86% | ― | -20.31% | -23.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $549.73M | -47.83 | -4.21% | ― | 121.11% | 80.74% | |
44 Neutral | $894.58M | -4.48 | -101.19% | ― | ― | -3.74% | |
43 Neutral | $800.60M | -4.37 | -78.12% | ― | ― | 7.21% |
* Healthcare Sector Average
AURA
Aura Biosciences Inc
7.74
1.58
25.65%
ASMB
Assembly Biosciences
27.74
9.18
49.46%
KRRO
Korro Bio
14.00
1.42
11.29%
ANNX
Annexon Biosciences
5.46
2.73
100.00%
FDMT
4D Molecular Therapeutics
13.00
9.05
229.11%
DSGN
Design Therapeutics
15.64
12.10
341.81%
Aura Biosciences Inc Corporate Events
Executive/Board ChangesShareholder Meetings
Aura Biosciences Announces Results of 2026 Annual Meeting
Positive
Jun 11, 2026
On June 11, 2026, Aura Biosciences, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected David Johnson and Teresa Marie Bitetti as Class II directors to serve on the board until the 2029 Annual Meeting, reinforcing continu...
Business Operations and StrategyExecutive/Board ChangesStock BuybackFinancial DisclosuresPrivate Placements and Financing
Aura Biosciences reports Q1 results, appoints new CEO
Positive
May 11, 2026
On May 11, 2026, Aura Biosciences reported first-quarter 2026 results and business developments, highlighting continued progress of its global Phase 3 CoMpass trial of bel-sar in early choroidal melanoma, which is expected to complete enrollment b...
Business Operations and StrategyStock BuybackPrivate Placements and Financing
Aura Biosciences Completes Major Underwritten Equity Financing
Positive
May 5, 2026
On May 4, 2026, Aura Biosciences Inc. entered into an underwriting agreement for an underwritten public offering of 39,591,000 common shares and 3,800,000 pre-funded warrants, with underwriters exercising in full a 6,508,650-share option, and the ...
Stock BuybackFinancial DisclosuresPrivate Placements and Financing
Aura Biosciences Announces Stock Repurchase Agreement with Shareholder
Positive
May 4, 2026
On April 30, 2026, Aura Biosciences entered into a stock purchase agreement with Matrix Capital Management Master Fund to repurchase up to 6,922,870 shares of its common stock, which represented Matrix’s entire 10.8% stake as of April 15, 20...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Aura Biosciences Advances CoMpass Phase 3 Trial Progress
Positive
May 4, 2026
On April 30, 2026, Aura Biosciences appointed veteran rare disease and oncology executive Natalie Holles as Chief Executive Officer, President and Class I director, succeeding founder Elisabet de los Pinos, who transitioned to a consulting role wi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.